NCT02341014

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.

Conditions

• T-cell Lymphomas
• Relapsed or Refractory

Interventions

Type	Name	Description
DRUG	Carfilzomib	The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
DRUG	Romidepsin
DRUG	Lenalidomide

Timeline

• Start date: 2015-01-02
• Primary completion: 2023-01-11
• Completion: 2023-01-11
• First posted: 2015-01-19
• Last updated: 2024-04-04
• Results posted: 2024-04-04

Locations

6 sites across 1 country: United States